Cargando…
A candidate molecular signature associated with tamoxifen failure in primary breast cancer
INTRODUCTION: Few markers are available that can predict response to tamoxifen treatment in estrogen receptor (ER)-positive breast cancers. Identification of such markers would be clinically useful. We attempted to identify molecular markers associated with tamoxifen failure in breast cancer. METHOD...
Autores principales: | Vendrell, Julie A, Robertson, Katherine E, Ravel, Patrice, Bray, Susan E, Bajard, Agathe, Purdie, Colin A, Nguyen, Catherine, Hadad, Sirwan M, Bieche, Ivan, Chabaud, Sylvie, Bachelot, Thomas, Thompson, Alastair M, Cohen, Pascale A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2614524/ https://www.ncbi.nlm.nih.gov/pubmed/18928543 http://dx.doi.org/10.1186/bcr2158 |
Ejemplares similares
-
Histological evaluation of AMPK signalling in primary breast cancer
por: Hadad, Sirwan M, et al.
Publicado: (2009) -
Validation of prognostic scores for survival in cancer patients beyond first-line therapy
por: Trédan, Olivier, et al.
Publicado: (2011) -
A methodological framework for drug development in rare diseases
por: Nony, Patrice, et al.
Publicado: (2014) -
Oestrogen Non-Genomic Signalling is Activated in Tamoxifen-Resistant Breast Cancer
por: Poulard, Coralie, et al.
Publicado: (2019) -
A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer
por: Hadad, Sirwan M., et al.
Publicado: (2016)